PathoQuest Raises $5M in Series B Round, Plans Clinical Trial of NGS-based Diagnostic | GenomeWeb

NEW YORK (GenomeWeb News) — PathoQuest, an infectious disease diagnostics startup based in Paris, has raised €3.8 million ($5 million) in a Series B private equity funding round, the company said today.

The firm, a 2010 spin-out from the Pasteur Institute and the Ecole Nationale Veterinaire d'Alfort, will use the funding for a clinical trial of a diagnostic assay it has been developing that combines next-generation sequencing and a cloud-based analysis software service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."